Case study: Optimization of lentiviral vector production from early stages to GMP

In this webinar we will share with the audience VIVEbiotech´s approach for developing lentiviral vectors from very early stages to GMP, considering highly relevant aspects such as scalability, regulatory compliance, and cost-effectiveness. Different manufacturing steps such as transient transfection using the PEIpro® reagent from Polyplus-transfection will be described.  

Attendees will grow their understanding of  

• LVV production requirements for scalability, regulatory compliance, and cost-effectiveness from early stages through to GMP. 
• How an optimized production process can be adapted to several intermediate scales, streamlining various developmental phases. 
• How to integrally manage LVV quality throughout the duration of the development project. 
• Quality being a key feature of suitability for the final product, we will also overview concepts of quality control and quality assurance.

Claire Wartel-Weill PhD

Director of Quality and Compliance, Polyplus-transfection

Claire Wartel has a PhD in Molecular Pharmacology and Pharmacochemistry from the University of Strasbourg (France, 1999). After several post-docs in different prestigious universities, Claire joined Polyplustransfection in 2004 as Cell Biology project leader and participated in the development of our flagship product jetPRIME®. Claire has taken Quality responsibility since 2007, and nowadays manages the department of Quality and Regulatory Affairs.

Natalia Elizalde PhD

Business Development Director, VIVEviotech

Rakel López de Maturana PhD

Qualified Person, VIVEBiotech

Doctor in Pharmacy (2003, University of Leeds). She started off her research activity in Pharmacology, studying the structure and function of G protein-coupled receptors (GPCRs) (Leeds, 1998-2002, MRC Edinburgh, 2002-2004). She has investigated the mechanisms of pathogenicity in neurodegenerative diseases for more than 10 years; first in Alzheimer’s disease (CIMA University of Navarra, 2005-2009) and later in Parkinson’s disease (Inbiomed Foundation and VIVEbioTECH, San Sebastian-Donostia, 2009-2016).

Watch now

SPEAKERS

Claire Wartel-Weill PhD

Director of Quality and Compliance, Polyplus-transfection

Natalia Elizalde PhD

Business Development Director, VIVEviotech

Rakel López de Maturana PhD

Qualified Person, VIVEBiotech

You might also like

Simplifying the transition from R&D to GMP-ready LNP production

Benjamin Knappett

16 May

Watch

Scalable solutions for optimizing lentiviral vector production

Vera Ortseifen, Kathrin Teschner

11 December

in 20

Days

Register

Case study: becoming the first GMP-certified cell and gene therapy manufacturing facility in Thailand

Kitipong Uaesoontrachoon

28 November 2023

Watch

Analytical strategies for sterility and mycoplasma testing in biotherapies: from early development to production scale-up

Sharon Rouw, Michael Brewer

3 July

Watch

Analytical strategies for sterility and mycoplasma testing in biotherapies: from early development to production scale-up

Sharon Rouw, Michael Brewer

4 April

Watch